The global market for First-in-Human (FIH) Services was valued at US$ 654 million in the year 2024 and is projected to reach a revised size of US$ 1298 million by 2031, growing at a CAGR of 11.3% during the forecast period.
First-in-Human Services refer to specialized services that support the planning, execution, and management of First-in-Human (FIH) clinical trials. These services are critical for the successful transition of a drug or therapeutic product from preclinical development to initial testing in human subjects. FIH trials are typically the first time a new drug is administered to humans, making the associated services essential for ensuring safety, compliance, and scientific validity.First-in-Human Services are essential for minimizing risks associated with the early testing of new drugs in humans, ensuring regulatory compliance, and generating reliable data that can influence subsequent phases of drug development. These services help streamline the clinical trial process, improve efficiency, and enhance the likelihood of successful product development.
North American market for First-in-Human (FIH) Services is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for First-in-Human (FIH) Services is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for First-in-Human (FIH) Services in Pharmaceutical Companies is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of First-in-Human (FIH) Services include WuXi AppTec, Allucent, Altasciences, LAXAI, Lonza, Syneos Health, CD BioSciences, Fortrea, Certara, Evotec, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for First-in-Human (FIH) Services, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding First-in-Human (FIH) Services.
The First-in-Human (FIH) Services market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global First-in-Human (FIH) Services market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the First-in-Human (FIH) Services companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
WuXi AppTec
Allucent
Altasciences
LAXAI
Lonza
Syneos Health
CD BioSciences
Fortrea
Certara
Evotec
Aixial Group
Quotient Sciences
Sofpromed
Spaulding Clinical
Biotrial
Crystal Pharmatech Co., Ltd
Avania
Segment by Type
Drugs
Medical Device
Segment by Application
Pharmaceutical Companies
Contract Research Organizations (CROs)
Academic Institutions and Research Centers
Medical Device Companies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of First-in-Human (FIH) Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global First-in-Human (FIH) Services 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Drugs
1.2.3 Medical Device
1.3 麻豆原创 by Application
1.3.1 Global First-in-Human (FIH) Services 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical Companies
1.3.3 Contract Research Organizations (CROs)
1.3.4 Academic Institutions and Research Centers
1.3.5 Medical Device Companies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global First-in-Human (FIH) Services 麻豆原创 Perspective (2020-2031)
2.2 Global First-in-Human (FIH) Services Growth Trends by Region
2.2.1 Global First-in-Human (FIH) Services 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 First-in-Human (FIH) Services Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 First-in-Human (FIH) Services Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 First-in-Human (FIH) Services 麻豆原创 Dynamics
2.3.1 First-in-Human (FIH) Services Industry Trends
2.3.2 First-in-Human (FIH) Services 麻豆原创 Drivers
2.3.3 First-in-Human (FIH) Services 麻豆原创 Challenges
2.3.4 First-in-Human (FIH) Services 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top First-in-Human (FIH) Services Players by Revenue
3.1.1 Global Top First-in-Human (FIH) Services Players by Revenue (2020-2025)
3.1.2 Global First-in-Human (FIH) Services Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global First-in-Human (FIH) Services 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by First-in-Human (FIH) Services Revenue
3.4 Global First-in-Human (FIH) Services 麻豆原创 Concentration Ratio
3.4.1 Global First-in-Human (FIH) Services 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by First-in-Human (FIH) Services Revenue in 2024
3.5 Global Key Players of First-in-Human (FIH) Services Head office and Area Served
3.6 Global Key Players of First-in-Human (FIH) Services, Product and Application
3.7 Global Key Players of First-in-Human (FIH) Services, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 First-in-Human (FIH) Services Breakdown Data by Type
4.1 Global First-in-Human (FIH) Services Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global First-in-Human (FIH) Services Forecasted 麻豆原创 Size by Type (2026-2031)
5 First-in-Human (FIH) Services Breakdown Data by Application
5.1 Global First-in-Human (FIH) Services Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global First-in-Human (FIH) Services Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America First-in-Human (FIH) Services 麻豆原创 Size (2020-2031)
6.2 North America First-in-Human (FIH) Services 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America First-in-Human (FIH) Services 麻豆原创 Size by Country (2020-2025)
6.4 North America First-in-Human (FIH) Services 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe First-in-Human (FIH) Services 麻豆原创 Size (2020-2031)
7.2 Europe First-in-Human (FIH) Services 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe First-in-Human (FIH) Services 麻豆原创 Size by Country (2020-2025)
7.4 Europe First-in-Human (FIH) Services 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific First-in-Human (FIH) Services 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific First-in-Human (FIH) Services 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific First-in-Human (FIH) Services 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific First-in-Human (FIH) Services 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America First-in-Human (FIH) Services 麻豆原创 Size (2020-2031)
9.2 Latin America First-in-Human (FIH) Services 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America First-in-Human (FIH) Services 麻豆原创 Size by Country (2020-2025)
9.4 Latin America First-in-Human (FIH) Services 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa First-in-Human (FIH) Services 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa First-in-Human (FIH) Services 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa First-in-Human (FIH) Services 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa First-in-Human (FIH) Services 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 WuXi AppTec
11.1.1 WuXi AppTec Company Details
11.1.2 WuXi AppTec Business Overview
11.1.3 WuXi AppTec First-in-Human (FIH) Services Introduction
11.1.4 WuXi AppTec Revenue in First-in-Human (FIH) Services Business (2020-2025)
11.1.5 WuXi AppTec Recent Development
11.2 Allucent
11.2.1 Allucent Company Details
11.2.2 Allucent Business Overview
11.2.3 Allucent First-in-Human (FIH) Services Introduction
11.2.4 Allucent Revenue in First-in-Human (FIH) Services Business (2020-2025)
11.2.5 Allucent Recent Development
11.3 Altasciences
11.3.1 Altasciences Company Details
11.3.2 Altasciences Business Overview
11.3.3 Altasciences First-in-Human (FIH) Services Introduction
11.3.4 Altasciences Revenue in First-in-Human (FIH) Services Business (2020-2025)
11.3.5 Altasciences Recent Development
11.4 LAXAI
11.4.1 LAXAI Company Details
11.4.2 LAXAI Business Overview
11.4.3 LAXAI First-in-Human (FIH) Services Introduction
11.4.4 LAXAI Revenue in First-in-Human (FIH) Services Business (2020-2025)
11.4.5 LAXAI Recent Development
11.5 Lonza
11.5.1 Lonza Company Details
11.5.2 Lonza Business Overview
11.5.3 Lonza First-in-Human (FIH) Services Introduction
11.5.4 Lonza Revenue in First-in-Human (FIH) Services Business (2020-2025)
11.5.5 Lonza Recent Development
11.6 Syneos Health
11.6.1 Syneos Health Company Details
11.6.2 Syneos Health Business Overview
11.6.3 Syneos Health First-in-Human (FIH) Services Introduction
11.6.4 Syneos Health Revenue in First-in-Human (FIH) Services Business (2020-2025)
11.6.5 Syneos Health Recent Development
11.7 CD BioSciences
11.7.1 CD BioSciences Company Details
11.7.2 CD BioSciences Business Overview
11.7.3 CD BioSciences First-in-Human (FIH) Services Introduction
11.7.4 CD BioSciences Revenue in First-in-Human (FIH) Services Business (2020-2025)
11.7.5 CD BioSciences Recent Development
11.8 Fortrea
11.8.1 Fortrea Company Details
11.8.2 Fortrea Business Overview
11.8.3 Fortrea First-in-Human (FIH) Services Introduction
11.8.4 Fortrea Revenue in First-in-Human (FIH) Services Business (2020-2025)
11.8.5 Fortrea Recent Development
11.9 Certara
11.9.1 Certara Company Details
11.9.2 Certara Business Overview
11.9.3 Certara First-in-Human (FIH) Services Introduction
11.9.4 Certara Revenue in First-in-Human (FIH) Services Business (2020-2025)
11.9.5 Certara Recent Development
11.10 Evotec
11.10.1 Evotec Company Details
11.10.2 Evotec Business Overview
11.10.3 Evotec First-in-Human (FIH) Services Introduction
11.10.4 Evotec Revenue in First-in-Human (FIH) Services Business (2020-2025)
11.10.5 Evotec Recent Development
11.11 Aixial Group
11.11.1 Aixial Group Company Details
11.11.2 Aixial Group Business Overview
11.11.3 Aixial Group First-in-Human (FIH) Services Introduction
11.11.4 Aixial Group Revenue in First-in-Human (FIH) Services Business (2020-2025)
11.11.5 Aixial Group Recent Development
11.12 Quotient Sciences
11.12.1 Quotient Sciences Company Details
11.12.2 Quotient Sciences Business Overview
11.12.3 Quotient Sciences First-in-Human (FIH) Services Introduction
11.12.4 Quotient Sciences Revenue in First-in-Human (FIH) Services Business (2020-2025)
11.12.5 Quotient Sciences Recent Development
11.13 Sofpromed
11.13.1 Sofpromed Company Details
11.13.2 Sofpromed Business Overview
11.13.3 Sofpromed First-in-Human (FIH) Services Introduction
11.13.4 Sofpromed Revenue in First-in-Human (FIH) Services Business (2020-2025)
11.13.5 Sofpromed Recent Development
11.14 Spaulding Clinical
11.14.1 Spaulding Clinical Company Details
11.14.2 Spaulding Clinical Business Overview
11.14.3 Spaulding Clinical First-in-Human (FIH) Services Introduction
11.14.4 Spaulding Clinical Revenue in First-in-Human (FIH) Services Business (2020-2025)
11.14.5 Spaulding Clinical Recent Development
11.15 Biotrial
11.15.1 Biotrial Company Details
11.15.2 Biotrial Business Overview
11.15.3 Biotrial First-in-Human (FIH) Services Introduction
11.15.4 Biotrial Revenue in First-in-Human (FIH) Services Business (2020-2025)
11.15.5 Biotrial Recent Development
11.16 Crystal Pharmatech Co., Ltd
11.16.1 Crystal Pharmatech Co., Ltd Company Details
11.16.2 Crystal Pharmatech Co., Ltd Business Overview
11.16.3 Crystal Pharmatech Co., Ltd First-in-Human (FIH) Services Introduction
11.16.4 Crystal Pharmatech Co., Ltd Revenue in First-in-Human (FIH) Services Business (2020-2025)
11.16.5 Crystal Pharmatech Co., Ltd Recent Development
11.17 Avania
11.17.1 Avania Company Details
11.17.2 Avania Business Overview
11.17.3 Avania First-in-Human (FIH) Services Introduction
11.17.4 Avania Revenue in First-in-Human (FIH) Services Business (2020-2025)
11.17.5 Avania Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
WuXi AppTec
Allucent
Altasciences
LAXAI
Lonza
Syneos Health
CD BioSciences
Fortrea
Certara
Evotec
Aixial Group
Quotient Sciences
Sofpromed
Spaulding Clinical
Biotrial
Crystal Pharmatech Co., Ltd
Avania
听
听
*If Applicable.
